FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2763680379> ?p ?o ?g. }

• W2763680379 endingPage "v627" @default.
• W2763680379 startingPage "v627" @default.
• W2763680379 abstract "Background: In the OVHIPEC study (NCT00426257), the addition of HIPEC to interval cytoreductive surgery (CRS) significantly improved recurrence-free (HR 0.66, 95% CI 0.50-0.87) and overall survival (HR 0.67, 95% CI 0.48-0.94) in patients with stage III ovarian cancer. We report the results of the health-related quality of life (HRQOL) analysis of patients in the OVHIPEC study. Methods: Patients who had at least stable disease after 3 cycles of carboplatin and paclitaxel were randomly assigned to receive interval CRS with (n = 122) or without (n = 123) HIPEC using cisplatin. Patients in both arms received 3 additional cycles of carboplatin/paclitaxel post-operatively. HRQOL was assessed using the EORTC core questionnaire (the QLQ-C30) and the ovarian and colorectal cancer modules (QLQ-OV28 and QLQ-CR38). HRQOL assessments were planned at least 2 weeks prior to surgery, after surgery, following the 6th chemotherapy cycle, and every three months thereafter until a maximum of two years of follow-up. HRQOL data were analysed using a mixed effect model. Current preliminary results pertain to the QLQ-C30 summary score, and the fatigue, neuropathy, micturition and gastrointestinal symptom scale scores for up to 1 year of follow-up or time of recurrence. Results: Of 245 randomized patients, 201 (82%) had at least one evaluable HRQOL assessment (93 for CRS arm, 108 for CRS+HIPEC arm). A linear mixed effects analysis indicated a significant group difference in QLQ-C30 summary scores over time (p = 0.047). The CRS group had modest improvement in overall HRQOL over time, while the CRS+HIPEC group remained largely unchanged. In both arms, the overall HRQOL scores were relatively high, both at baseline and during follow-up. No significant group differences over time were observed for fatigue, neuropathy, micturition or gastrointestinal symptoms. Conclusions: Preliminary results indicate that patients in this trial had relatively high overall HRQOL scores, that tended to improve more over time in the CRS arm compared to the CRS+HIPEC arm. Future analyses will yield additional information about the specific patterns of HRQOL and symptom effects over the course of the trial. Clinical trial identification: NCT00426257 Legal entity responsible for the study: The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Funding: None Disclosure: All authors have declared no conflicts of interest." @default.
• W2763680379 created "2017-10-20" @default.
• W2763680379 creator A5001308210 @default.
• W2763680379 creator A5016399717 @default.
• W2763680379 creator A5024224158 @default.
• W2763680379 creator A5025082485 @default.
• W2763680379 creator A5030950283 @default.
• W2763680379 creator A5035775742 @default.
• W2763680379 creator A5037246030 @default.
• W2763680379 creator A5039468626 @default.
• W2763680379 creator A5058424202 @default.
• W2763680379 creator A5071418370 @default.
• W2763680379 creator A5071780971 @default.
• W2763680379 creator A5075030358 @default.
• W2763680379 creator A5082015784 @default.
• W2763680379 creator A5085096954 @default.
• W2763680379 creator A5088241536 @default.
• W2763680379 creator A5091317585 @default.
• W2763680379 date "2017-09-01" @default.
• W2763680379 modified "2023-09-30" @default.
• W2763680379 title "Health-related quality of life after hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer: Results of the phase III OVHIPEC study" @default.
• W2763680379 doi "https://doi.org/10.1093/annonc/mdx440.037" @default.
• W2763680379 hasPublicationYear "2017" @default.
• W2763680379 type Work @default.
• W2763680379 sameAs 2763680379 @default.
• W2763680379 citedByCount "0" @default.
• W2763680379 crossrefType "journal-article" @default.
• W2763680379 hasAuthorship W2763680379A5001308210 @default.
• W2763680379 hasAuthorship W2763680379A5016399717 @default.
• W2763680379 hasAuthorship W2763680379A5024224158 @default.
• W2763680379 hasAuthorship W2763680379A5025082485 @default.
• W2763680379 hasAuthorship W2763680379A5030950283 @default.
• W2763680379 hasAuthorship W2763680379A5035775742 @default.
• W2763680379 hasAuthorship W2763680379A5037246030 @default.
• W2763680379 hasAuthorship W2763680379A5039468626 @default.
• W2763680379 hasAuthorship W2763680379A5058424202 @default.
• W2763680379 hasAuthorship W2763680379A5071418370 @default.
• W2763680379 hasAuthorship W2763680379A5071780971 @default.
• W2763680379 hasAuthorship W2763680379A5075030358 @default.
• W2763680379 hasAuthorship W2763680379A5082015784 @default.
• W2763680379 hasAuthorship W2763680379A5085096954 @default.
• W2763680379 hasAuthorship W2763680379A5088241536 @default.
• W2763680379 hasAuthorship W2763680379A5091317585 @default.
• W2763680379 hasBestOaLocation W27636803791 @default.
• W2763680379 hasConcept C121608353 @default.
• W2763680379 hasConcept C126322002 @default.
• W2763680379 hasConcept C141071460 @default.
• W2763680379 hasConcept C143998085 @default.
• W2763680379 hasConcept C146357865 @default.
• W2763680379 hasConcept C151730666 @default.
• W2763680379 hasConcept C159110408 @default.
• W2763680379 hasConcept C2776694085 @default.
• W2763680379 hasConcept C2778239845 @default.
• W2763680379 hasConcept C2779458272 @default.
• W2763680379 hasConcept C2779951463 @default.
• W2763680379 hasConcept C2780427987 @default.
• W2763680379 hasConcept C2781451048 @default.
• W2763680379 hasConcept C2994223192 @default.
• W2763680379 hasConcept C44249647 @default.
• W2763680379 hasConcept C71924100 @default.
• W2763680379 hasConcept C86803240 @default.
• W2763680379 hasConceptScore W2763680379C121608353 @default.
• W2763680379 hasConceptScore W2763680379C126322002 @default.
• W2763680379 hasConceptScore W2763680379C141071460 @default.
• W2763680379 hasConceptScore W2763680379C143998085 @default.
• W2763680379 hasConceptScore W2763680379C146357865 @default.
• W2763680379 hasConceptScore W2763680379C151730666 @default.
• W2763680379 hasConceptScore W2763680379C159110408 @default.
• W2763680379 hasConceptScore W2763680379C2776694085 @default.
• W2763680379 hasConceptScore W2763680379C2778239845 @default.
• W2763680379 hasConceptScore W2763680379C2779458272 @default.
• W2763680379 hasConceptScore W2763680379C2779951463 @default.
• W2763680379 hasConceptScore W2763680379C2780427987 @default.
• W2763680379 hasConceptScore W2763680379C2781451048 @default.
• W2763680379 hasConceptScore W2763680379C2994223192 @default.
• W2763680379 hasConceptScore W2763680379C44249647 @default.
• W2763680379 hasConceptScore W2763680379C71924100 @default.
• W2763680379 hasConceptScore W2763680379C86803240 @default.
• W2763680379 hasLocation W27636803791 @default.
• W2763680379 hasOpenAccess W2763680379 @default.
• W2763680379 hasPrimaryLocation W27636803791 @default.
• W2763680379 hasRelatedWork W1481820868 @default.
• W2763680379 hasRelatedWork W2010230997 @default.
• W2763680379 hasRelatedWork W2067366728 @default.
• W2763680379 hasRelatedWork W2072767112 @default.
• W2763680379 hasRelatedWork W2320097775 @default.
• W2763680379 hasRelatedWork W2417634857 @default.
• W2763680379 hasRelatedWork W2471989939 @default.
• W2763680379 hasRelatedWork W2811275011 @default.
• W2763680379 hasRelatedWork W4302319510 @default.
• W2763680379 hasRelatedWork W78466149 @default.
• W2763680379 hasVolume "28" @default.
• W2763680379 isParatext "false" @default.
• W2763680379 isRetracted "false" @default.
• W2763680379 magId "2763680379" @default.
• W2763680379 workType "article" @default.